Cancer cells exhibit altered metabolic pathways to keep up with biosynthetic and reduction–oxidation needs during tumor proliferation and metastasis. The common induction of metabolic pathways during cancer progression, regardless of cancer histio- or genotype, makes cancer metabolism an attractive target for therapeutic exploitation.
Recent Advances:
Emerging data suggest that these altered pathways may even result in resistance to anticancer therapies. Identifying specific metabolic dependencies that are unique to cancer cells has proved challenging in this field, limiting the therapeutic window for many candidate drug approaches.
Critical Issues:
Cancer cells display significant metabolic flexibility in nutrient-limited environments, hampering the longevity of suppressing cancer metabolism through any singular approach. Combinatorial “synthetic lethal” approaches may have a better chance for success and promising strategies are reviewed here. The dynamism of the immune system adds a level of complexity, as various immune populations in the tumor microenvironment often share metabolic pathways with cancer, with successive alterations during immune activation and quiescence. Decoding the reprogramming of metabolic pathways within cancer cells and stem cells, as well as examining metabolic symbiosis between components of the tumor microenvironment, would be essential to further meaningful drug development within the tumor's metabolic ecosystem.
Future Directions:
In this article, we examine evidence for the therapeutic potential of targeting metabolic alterations in cancer, and we discuss the drawbacks and successes that have stimulated this field.
Get full access to this article
View all access options for this article.
References
1.
AhsanA.Mechanisms of resistance to EGFR tyrosine kinase inhibitors and therapeutic approaches: an update. Adv Exp Med Biol, 893: 137–153, 2016.
2.
AlgireC, AmreinL, BazileM, DavidS, ZakikhaniM, and PollakM. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene, 30: 1174–1182, 2011.
3.
AlistarA, MorrisBB, DesnoyerR, KlepinHD, HosseinzadehK, ClarkC, CameronA, LeyendeckerJ, D'AgostinoRJr., TopalogluU, BotejuLW, BotejuAR, ShorrR, ZacharZ, BinghamPM, AhmedT, CraneS, ShahR, MiglianoJJ, PardeeTS, MillerL, HawkinsG, JinG, ZhangW, and PascheB.Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncol, 18: 770–778, 2017.
4.
AltmanBJ, StineZE, and DangCV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer, 16: 749, 2016.
5.
AntoniewiczMR.A guide to (13)C metabolic flux analysis for the cancer biologist. Exp Mol Med, 50: 19, 2018.
6.
BaenkeF, ChanetonB, SmithM, Van Den BroekN, HoganK, TangH, VirosA, MartinM, GalbraithL, GirottiMR, DhomenN, GottliebE, and MaraisR. Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells. Mol Oncol, 10: 73–84, 2016.
BauerDE, HatzivassiliouG, ZhaoF, AndreadisC, and ThompsonCB. ATP citrate lyase is an important component of cell growth and transformation. Oncogene, 24: 6314–6322, 2005.
9.
BhutiaYD, BabuE, and GanapathyV. Re-programming tumour cell metabolism to treat cancer: no lone target for lonidamine. Biochem J, 473: 1503–1506, 2016.
10.
BirsoyK, PossematoR, LorbeerFK, BayraktarEC, ThiruP, YucelB, WangT, ChenWW, ClishCB, and SabatiniDM. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature, 508: 108–112, 2014.
11.
BiswasSK.Metabolic reprogramming of immune cells in cancer progression. Immunity, 43: 435–449, 2015.
BowkerSL, MajumdarSR, VeugelersP, and JohnsonJA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care, 29: 254–258, 2006.
14.
BradleyCA.Glutamine-fuelled OXPHOS—a new target in MCL. Nat Rev Cancer, 19: 363, 2019.
15.
BrusselmansK, VrolixR, VerhoevenG, and SwinnenJV. Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. J Biol Chem, 280: 5636–5645, 2005.
16.
BuckMD, SowellRT, KaechSM, and PearceEL. Metabolic instruction of immunity. Cell, 169: 570–586, 2017.
17.
BudcziesJ, PfitznerBM, GyorffyB, WinzerKJ, RadkeC, DietelM, FiehnO, and DenkertC. Glutamate enrichment as new diagnostic opportunity in breast cancer. Int J Cancer, 136: 1619–1628, 2015.
18.
BuzzaiM, BauerDE, JonesRG, DeberardinisRJ, HatzivassiliouG, ElstromRL, and ThompsonCB. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene, 24: 4165–4173, 2005.
19.
CantorJR and SabatiniDM. Cancer cell metabolism: one hallmark, many faces. Cancer Discov, 2: 881–898, 2012.
20.
CapelloM, Ferri-BorgognoS, RigantiC, ChattaragadaMS, PrincipeM, RouxC, ZhouW, PetricoinEF, CappelloP, and NovelliF. Targeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest. Oncotarget, 7: 5598–5612, 2016.
21.
CapperD, WeissertS, BalssJ, HabelA, MeyerJ, JagerD, AckermannU, TessmerC, KorshunovA, ZentgrafH, HartmannC, and von DeimlingA. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol, 20: 245–254, 2010.
22.
CarrEL, KelmanA, WuGS, GopaulR, SenkevitchE, AghvanyanA, TurayAM, and FrauwirthKA. Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK during T lymphocyte activation. J Immunol, 185: 1037–1044, 2010.
23.
ChajesV, CambotM, MoreauK, LenoirGM, and JoulinV. Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. Cancer Res, 66: 5287–5294, 2006.
24.
ChristofkHR, Vander HeidenMG, HarrisMH, RamanathanA, GersztenRE, WeiR, FlemingMD, SchreiberSL, and CantleyLC. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature, 452: 230–233, 2008.
25.
ClemBF, O'NealJ, TapolskyG, ClemAL, Imbert-FernandezY, KerrDA, 2nd, KlarerAC, RedmanR, MillerDM, TrentJO, TelangS, and ChesneyJ. Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. Mol Cancer Ther, 12: 1461–1470, 2013.
26.
CommissoC, DavidsonSM, Soydaner-AzelogluRG, ParkerSJ, KamphorstJJ, HackettS, GrabockaE, NofalM, DrebinJA, ThompsonCB, RabinowitzJD, MetalloCM, Vander HeidenMG, and Bar-SagiD. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature, 497: 633–637, 2013.
27.
ConsortiumGT.Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science, 348: 648–660, 2015.
28.
Cortes-CrosM, HemmerlinC, FerrettiS, ZhangJ, GounaridesJS, YinH, MullerA, HaberkornA, CheneP, SellersWR, and HofmannF. M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth. Proc Natl Acad Sci U S A, 110: 489–494, 2013.
29.
DanL, WangC, MaP, YuQ, GuM, DongL, JiangW, PanS, XieC, HanJ, LanY, SunJ, ShengP, LiuK, WuY, LiuL, MaY, and JiangH. PGC1alpha promotes cholangiocarcinoma metastasis by upregulating PDHA1 and MPC1 expression to reverse the Warburg effect. Cell Death Dis, 9: 466, 2018.
30.
DangCV.c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol, 19: 1–11, 1999.
de Lera RuizM, LimYH, and ZhengJ. Adenosine A2A receptor as a drug discovery target. J Med Chem, 57: 3623–3650, 2014.
33.
De RosaV, IommelliF, MontiM, FontiR, VottaG, StoppelliMP, and Del VecchioS. Reversal of Warburg effect and reactivation of oxidative phosphorylation by differential inhibition of EGFR signaling pathways in non-small cell lung cancer. Clin Cancer Res, 21: 5110–5120, 2015.
34.
DeBerardinisRJ and ChandelNS. Fundamentals of cancer metabolism. Sci Adv, 2: e1600200, 2016.
35.
DiNardoCD, SteinEM, de BottonS, RobozGJ, AltmanJK, MimsAS, SwordsR, CollinsRH, MannisGN, PollyeaDA, DonnellanW, FathiAT, PigneuxA, ErbaHP, PrinceGT, SteinAS, UyGL, ForanJM, TraerE, StuartRK, ArellanoML, SlackJL, SekeresMA, WillekensC, ChoeS, WangH, ZhangV, YenKE, KapsalisSM, YangH, DaiD, FanB, GoldwasserM, LiuH, AgrestaS, WuB, AttarEC, TallmanMS, StoneRM, and KantarjianHM. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med, 378: 2386–2398, 2018.
36.
DuvelK, YeciesJL, MenonS, RamanP, LipovskyAI, SouzaAL, TriantafellowE, MaQ, GorskiR, CleaverS, Vander HeidenMG, MacKeiganJP, FinanPM, ClishCB, MurphyLO, and ManningBD. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell, 39: 171–183, 2010.
37.
EllinghausP, HeislerI, UnterschemmannK, HaerterM, BeckH, GreschatS, EhrmannA, SummerH, FlammeI, OehmeF, ThierauchK, MichelsM, Hess-StumppH, and ZiegelbauerK. BAY 87–2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I. Cancer Med, 2: 611–624, 2013.
38.
ElstromRL, BauerDE, BuzzaiM, KarnauskasR, HarrisMH, PlasDR, ZhuangH, CinalliRM, AlaviA, RudinCM, and ThompsonCB. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res, 64: 3892–3899, 2004.
39.
FengY and WuL. mTOR up-regulation of PFKFB3 is essential for acute myeloid leukemia cell survival. Biochem Biophys Res Commun, 483: 897–903, 2017.
40.
FlavinR, PelusoS, NguyenPL, and LodaM. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol, 6: 551–562, 2010.
41.
FrancescoMED, MarszalekJR, McAfoosT, CarrollCL, KangZ, LiuG, TheroffJP, BardenhagerJP, BandiML, MolinaJR, GeraS, ProtopopovaM, SunY, DoMKG, FengN, GayJP, MullerF, KonoplevaM, Meric-BernstamF, ToniattiC, HeffernanTP, DraettaGF, and JonesP. Abstract 1655: discovery and development of IACS-010759, a novel inhibitor of complex I currently in phase I studies to exploit oxidative phosphorylation dependency in acute myeloid leukemia and solid tumors. Cancer Res, 78: 1655, 2018.
42.
FribergM, JenningsR, AlsarrajM, DessureaultS, CantorA, ExtermannM, MellorAL, MunnDH, and AntoniaSJ. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer, 101: 151–155, 2002.
43.
FunesJM, QuinteroM, HendersonS, MartinezD, QureshiU, WestwoodC, ClementsMO, BourbouliaD, PedleyRB, MoncadaS, and BoshoffC. Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. Proc Natl Acad Sci U S A, 104: 6223–6228, 2007.
44.
GabrilovichDI, Ostrand-RosenbergS, and BronteV. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol, 12: 253–268, 2012.
45.
GalluzziL, KeppO, Vander HeidenMG, and KroemerG. Metabolic targets for cancer therapy. Nat Rev Drug Discov, 12: 829–846, 2013.
46.
GaoP, TchernyshyovI, ChangTC, LeeYS, KitaK, OchiT, ZellerKI, De MarzoAM, Van EykJE, MendellJT, and DangCV. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature, 458: 762–765, 2009.
47.
GeierA, MaciasRI, BettingerD, WeissJ, BantelH, JahnD, Al-AbdullaR, and MarinJJ. The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma. Oncotarget, 8: 15846–15857, 2017.
48.
GeniniD, BrambillaL, LauriniE, MerullaJ, CivenniG, PanditS, D'AntuonoR, PerezL, LevyDE, PriclS, CarboneGM, and CatapanoCV. Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells. Proc Natl Acad Sci U S A, 114: E4924–E4933, 2017.
49.
GiannakisM, LiH, JinC, GopalS, DesaiK, HorakC, Wind-RotoloM, AllenEMV, ClishC, HodiFS, GarrawayLA, and ChoueiriTK. Metabolomic correlates of response in nivolumab-treated renal cell carcinoma and melanoma patients. J Clin Oncol, 35: 3036, 2017.
50.
GonenN and AssarafYG. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat, 15: 183–210, 2012.
51.
GrohmannU and BronteV. Control of immune response by amino acid metabolism. Immunol Rev, 236: 243–264, 2010.
52.
GrossM, ChenJ, EnglertJ, JanesJ, LeoneR, MacKinnonA, ParlatiF, RodriquezM, ShwonekP, and PowellJ. Abstract 2329: glutaminase inhibition with CB-839 enhances anti-tumor activity of PD-1 and PD-L1 antibodies by overcoming a metabolic checkpoint blocking T cell activation. Cancer Res, 76: 2329, 2016.
53.
GrossMI, DemoSD, DennisonJB, ChenL, Chernov-RoganT, GoyalB, JanesJR, LaidigGJ, LewisER, LiJ, MackinnonAL, ParlatiF, RodriguezML, ShwonekPJ, SjogrenEB, StantonTF, WangT, YangJ, ZhaoF, and BennettMK. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther, 13: 890–901, 2014.
54.
HanK, JengEE, HessGT, MorgensDW, LiA, and BassikMC. Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions. Nat Biotechnol, 35: 463–474, 2017.
55.
HanahanD and CoussensLM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell, 21: 309–322, 2012.
56.
HanahanD and WeinbergRA. Hallmarks of cancer: the next generation. Cell, 144: 646–674, 2011.
57.
HaqR.Metabolic dysregulation in melanoma: cause or consequence?. Cancer Discov, 4: 390–391, 2014.
58.
HaqR, ShoagJ, Andreu-PerezP, YokoyamaS, EdelmanH, RoweGC, FrederickDT, HurleyAD, NelloreA, KungAL, WargoJA, SongJS, FisherDE, AranyZ, and WidlundHR. Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell, 23: 302–315, 2013.
59.
HatzivassiliouG, ZhaoF, BauerDE, AndreadisC, ShawAN, DhanakD, HingoraniSR, TuvesonDA, and ThompsonCB. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell, 8: 311–321, 2005.
60.
HensleyCT, WastiAT, and DeBerardinisRJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest, 123: 3678–3684, 2013.
61.
HeuerTS, VenturaR, MordecK, LaiJ, FridlibM, BuckleyD, and KembleG. FASN inhibition and taxane treatment combine to enhance anti-tumor efficacy in diverse xenograft tumor models through disruption of tubulin palmitoylation and microtubule organization and FASN inhibition-mediated effects on oncogenic signaling and gene expression. EBioMedicine, 16: 51–62, 2017.
62.
HirparaJ, EuJQ, TanJKM, WongAL, ClementMV, KongLR, OhiN, TsunodaT, QuJ, GohBC, and PervaizS. Metabolic reprogramming of oncogene-addicted cancer cells to OXPHOS as a mechanism of drug resistance. Redox Biol, 25: 101076, 2019.
63.
HoppertonKE, DuncanRE, BazinetRP, and ArcherMC. Fatty acid synthase plays a role in cancer metabolism beyond providing fatty acids for phospholipid synthesis or sustaining elevations in glycolytic activity. Exp Cell Res, 320: 302–310, 2014.
64.
HorbinskiC, KoflerJ, KellyLM, MurdochGH, and NikiforovaMN. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol, 68: 1319–1325, 2009.
65.
HornyakL, DobosN, KonczG, KaranyiZ, PallD, SzaboZ, HalmosG, and SzekvolgyiL. The role of indoleamine-2,3-dioxygenase in cancer development, diagnostics, and therapy. Front Immunol, 9: 151, 2018.
66.
HuW, ZhangC, WuR, SunY, LevineA, and FengZ. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci U S A, 107: 7455–7460, 2010.
67.
IskandarK, RezlanM, YadavSK, FooCH, SethiG, QiangY, BellotGL, and PervaizS. Synthetic lethality of a novel small molecule against mutant KRAS-expressing cancer cells involves AKT-dependent ROS production. Antioxid Redox Signal, 24: 781–794, 2016.
68.
JainM, NilssonR, SharmaS, MadhusudhanN, KitamiT, SouzaAL, KafriR, KirschnerMW, ClishCB, and MoothaVK. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science, 336: 1040–1044, 2012.
69.
JaninM, MylonasE, SaadaV, MicolJB, RennevilleA, QuivoronC, KoscielnyS, ScourzicL, ForgetS, PautasC, CaillotD, PreudhommeC, DombretH, BerthonC, BaroukiR, RabierD, AugerN, GriscelliF, ChachatyE, LeclercqE, CourtierMH, Bennaceur-GriscelliA, SolaryE, BernardOA, Penard-LacroniqueV, OttolenghiC, and de BottonS. Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol, 32: 297–305, 2014.
70.
JeonSM, ChandelNS, and HayN. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature, 485: 661–665, 2012.
71.
JhaAK, HuangSC, SergushichevA, LampropoulouV, IvanovaY, LoginichevaE, ChmielewskiK, StewartKM, AshallJ, EvertsB, PearceEJ, DriggersEM, and ArtyomovMN. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity, 42: 419–430, 2015.
72.
JiralerspongS, PallaSL, GiordanoSH, Meric-BernstamF, LiedtkeC, BarnettCM, HsuL, HungMC, HortobagyiGN, and Gonzalez-AnguloAM. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol, 27: 3297–3302, 2009.
73.
JoseC, BellanceN, and RossignolR. Choosing between glycolysis and oxidative phosphorylation: a tumor's dilemma?. Biochim Biophys Acta, 1807: 552–561, 2011.
74.
JunttilaMR and de SauvageFJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature, 501: 346–354, 2013.
75.
KaushikAK and DeBerardinisRJ. Applications of metabolomics to study cancer metabolism. Biochim Biophys Acta Rev Cancer, 1870: 2–14, 2018.
76.
KonkelB, CaflischLD, DuqueAED, MichalekJ, LiuQ, and BrennerAJ. Prospective phase II trial in patients with first relapse of high-grade astrocytoma using TVB-2640 in combination with bevacizumab versus bevacizumab alone. J Clin Oncol, 37: 2064, 2019.
77.
KungC, HixonJ, ChoeS, MarksK, GrossS, MurphyE, DeLaBarreB, CianchettaG, SethumadhavanS, WangX, YanS, GaoY, FangC, WeiW, JiangF, WangS, QianK, SaundersJ, DriggersE, WooHK, KuniiK, MurrayS, YangH, YenK, LiuW, CantleyLC, Vander HeidenMG, SuSM, JinS, SalituroFG, and DangL. Small molecule activation of PKM2 in cancer cells induces serine auxotrophy. Chem Biol, 19: 1187–1198, 2012.
78.
KungHN, MarksJR, and ChiJT. Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia. PLoS Genet, 7: e1002229, 2011.
LamarZS, IsomS, VaidyaR, BeavenAW, and McIverZA. Phase I dose-escalation study of Cpi-613, in combination with bendamustine, in relapsed or refractory T-cell non-Hodgkin lymphoma. Blood, 128: 4163, 2016.
81.
LampropoulouV, SergushichevA, BambouskovaM, NairS, VincentEE, LoginichevaE, Cervantes-BarraganL, MaX, HuangSC, GrissT, WeinheimerCJ, KhaderS, RandolphGJ, PearceEJ, JonesRG, DiwanA, DiamondMS, and ArtyomovMN. Itaconate links inhibition of succinate dehydrogenase with macrophage metabolic remodeling and regulation of inflammation. Cell Metab, 24: 158–166, 2016.
82.
LarmanTC, DePalmaSR, HadjipanayisAG; Cancer Genome Atlas Research Network, ProtopopovA, ZhangJ, GabrielSB, ChinL, SeidmanCE, KucherlapatiR, and SeidmanJG. Spectrum of somatic mitochondrial mutations in five cancers. Proc Natl Acad Sci U S A, 109: 14087–14091, 2012.
83.
LeBleuVS, O'ConnellJT, Gonzalez HerreraKN, WikmanH, PantelK, HaigisMC, de CarvalhoFM, DamascenaA, Domingos ChinenLT, RochaRM, AsaraJM, and KalluriR. PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol, 16: 992–1003, 1–15, 2014.
84.
LeeJH, JangH, LeeSM, LeeJE, ChoiJ, KimTW, ChoEJ, and YounHD. ATP-citrate lyase regulates cellular senescence via an AMPK- and p53-dependent pathway. FEBS J, 282: 361–371, 2015.
85.
LeeKM, GiltnaneJM, BalkoJM, SchwarzLJ, Guerrero-ZotanoAL, HutchinsonKE, NixonMJ, EstradaMV, SanchezV, SandersME, LeeT, GomezH, LluchA, Perez-FidalgoJA, WolfMM, AndrejevaG, RathmellJC, FesikSW, and ArteagaCL. MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation. Cell Metab, 26: 633.e7–647.e7, 2017.
86.
LeeSY, JeonHM, JuMK, JeongEK, KimCH, ParkHG, HanSI, and KangHS. Dlx-2 and glutaminase upregulate epithelial-mesenchymal transition and glycolytic switch. Oncotarget, 7: 7925–7939, 2016.
87.
LevineAJ and Puzio-KuterAM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science, 330: 1340–1344, 2010.
88.
LinJJ, RielyGJ, and ShawAT. Targeting ALK: precision medicine takes on drug resistance. Cancer Discov, 7: 137–155, 2017.
89.
LisantiMP, Martinez-OutschoornUE, and SotgiaF. Oncogenes induce the cancer-associated fibroblast phenotype: metabolic symbiosis and “fibroblast addiction” are new therapeutic targets for drug discovery. Cell Cycle, 12: 2723–2732, 2013.
90.
Lissanu DeribeY, SunY, TerranovaC, KhanF, Martinez-LedesmaJ, GayJ, GaoG, MullinaxRA, KhorT, FengN, LinYH, WuCC, ReyesC, PengQ, RobinsonF, InoueA, KochatV, LiuCG, AsaraJM, MoranC, MullerF, WangJ, FangB, PapadimitrakopoulouV, WistubaII, RaiK, MarszalekJ, and FutrealPA. Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer. Nat Med, 24: 1047–1057, 2018.
91.
LongGV, DummerR, HamidO, GajewskiTF, CaglevicC, DalleS, AranceA, CarlinoMS, GrobJJ, KimTM, DemidovL, RobertC, LarkinJ, AndersonJR, MaleskiJ, JonesM, DiedeSJ, and MitchellTC. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol, 20: P1083–1097, 2019.
92.
LuengoA, GuiDY, and Vander HeidenMG. Targeting metabolism for cancer therapy. Cell Chem Biol, 24: 1161–1180, 2017.
93.
MacIverNJ, MichalekRD, and RathmellJC. Metabolic regulation of T lymphocytes. Annu Rev Immunol, 31: 259–283, 2013.
94.
MarcucciG, MaharryK, WuYZ, RadmacherMD, MrozekK, MargesonD, HollandKB, WhitmanSP, BeckerH, SchwindS, MetzelerKH, PowellBL, CarterTH, KolitzJE, WetzlerM, CarrollAJ, BaerMR, CaligiuriMA, LarsonRA, and BloomfieldCD. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol, 28: 2348–2355, 2010.
95.
MartinMJ, EberleinC, TaylorM, AshtonS, RobinsonD, and CrossD. Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma. Oncotarget, 7: 86313–86325, 2016.
96.
Martinez-OutschoornUE, Peiris-PagesM, PestellRG, SotgiaF, and LisantiMP. Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol, 14: 11–31, 2017.
97.
McMillinDW, NegriJM, and MitsiadesCS. The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov, 12: 217–228, 2013.
98.
MedeirosBC, FathiAT, DiNardoCD, PollyeaDA, ChanSM, and SwordsR. Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia, 31: 272–281, 2017.
99.
MenendezJA, VellonL, MehmiI, OzaBP, RoperoS, ColomerR, and LupuR. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci U S A, 101: 10715–10720, 2004.
100.
Meric-BernstamF, LeeRJ, CarthonBC, IliopoulosO, MierJW, PatelMR, TannirNM, OwonikokoTK, HaasNB, VossMH, HardingJJ, SrinivasanR, ShapiroG, TelliML, MunsterPN, CarvajalRD, JenkinsY, WhitingSH, BendellJC, and BauerTM. CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): results of a phase I study. J Clin Oncol, 37: 549, 2019.
101.
MigitaT, NaritaT, NomuraK, MiyagiE, InazukaF, MatsuuraM, UshijimaM, MashimaT, SeimiyaH, SatohY, OkumuraS, NakagawaK, and IshikawaY. ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res, 68: 8547–8554, 2008.
102.
MillerDM, ThomasSD, IslamA, MuenchD, and SedorisK. c-Myc and cancer metabolism. Clin Cancer Res, 18: 5546–5553, 2012.
103.
MitchellTC, HamidO, SmithDC, BauerTM, WasserJS, OlszanskiAJ, LukeJJ, BalmanoukianAS, SchmidtEV, ZhaoY, GongX, MaleskiJ, LeopoldL, and GajewskiTF. Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037). J Clin Oncol, 36: 3223–3230, 2018.
104.
MolenaarRJ, RadivoyevitchT, MaciejewskiJP, van NoordenCJ, and BleekerFE. The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. Biochim Biophys Acta, 1846: 326–341, 2014.
MullardA.Cancer metabolism pipeline breaks new ground. Nat Rev Drug Discov, 15: 735–737, 2016.
107.
NagarajanA, MalviP, and WajapeyeeN. Oncogene-directed alterations in cancer cell metabolism. Trends Cancer, 2: 365–377, 2016.
108.
NathK, GuoL, NancolasB, NelsonDS, ShestovAA, LeeSC, RomanJ, ZhouR, LeeperDB, HalestrapAP, BlairIA, and GlicksonJD. Mechanism of antineoplastic activity of lonidamine. Biochim Biophys Acta, 1866: 151–162, 2016.
109.
NewsholmeP.Why is l-glutamine metabolism important to cells of the immune system in health, postinjury, surgery or infection?. J Nutr, 131: 2515S-22S; discussion 2523S-4S, 2001.
110.
O'NealJ, ClemA, ReynoldsL, DoughertyS, Imbert-FernandezY, TelangS, ChesneyJ, and ClemBF. Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer. Breast Cancer Res Treat, 160: 29–40, 2016.
111.
OguraM, UchidaT, TeruiY, HayakawaF, KobayashiY, TaniwakiM, TakamatsuY, NaoeT, TobinaiK, MunakataW, YamauchiT, KageyamaA, YuasaM, MotoyamaM, TsunodaT, and HatakeK. Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies. Cancer Sci, 106: 896–901, 2015.
112.
OritaH, CoulterJ, LemmonC, TullyE, VadlamudiA, MedghalchiSM, KuhajdaFP, and GabrielsonE. Selective inhibition of fatty acid synthase for lung cancer treatment. Clin Cancer Res, 13: 7139–7145, 2007.
113.
OritaH, CoulterJ, TullyE, KuhajdaFP, and GabrielsonE. Inhibiting fatty acid synthase for chemoprevention of chemically induced lung tumors. Clin Cancer Res, 14: 2458–2464, 2008.
114.
OwenMR, DoranE, and HalestrapAP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J, 348(Pt3): 607–614, 2000.
115.
Palsson-McDermottEM, CurtisAM, GoelG, LauterbachMA, SheedyFJ, GleesonLE, van den BoschMW, QuinnSR, Domingo-FernandezR, JohnstonDG, JiangJK, IsraelsenWJ, KeaneJ, ThomasC, ClishC, Vander HeidenM, XavierRJ, and O'NeillLA. Pyruvate kinase M2 regulates Hif-1alpha activity and IL-1beta induction and is a critical determinant of the Warburg effect in LPS-activated macrophages. Cell Metab, 21: 65–80, 2015.
116.
ParkerSJ, SvenssonRU, DivakaruniAS, LefebvreAE, MurphyAN, ShawRJ, and MetalloCM. LKB1 promotes metabolic flexibility in response to energy stress. Metab Eng, 43: 208–217, 2017.
117.
PavlovaNN and ThompsonCB. The emerging hallmarks of cancer metabolism. Cell Metab, 23: 27–47, 2016.
118.
PerezRP, RieseMJ, LewisKD, SalehMN, DaudA, BerlinJ, LeeJJ, MukhopadhyayS, ZhouL, SerbestG, and HamidO. Epacadostat plus nivolumab in patients with advanced solid tumors: preliminary phase I/II results of ECHO-204. J Clin Oncol, 35: 3003, 2017.
119.
PollakM.Potential applications for biguanides in oncology. J Clin Invest, 123: 3693–3700, 2013.
120.
PollakM.Overcoming drug development bottlenecks with repurposing: repurposing biguanides to target energy metabolism for cancer treatment. Nat Med, 20: 591–593, 2014.
121.
QianX, XuW, XuJ, ShiQ, LiJ, WengY, JiangZ, FengL, WangX, ZhouJ, and JinH. Enolase 1 stimulates glycolysis to promote chemoresistance in gastric cancer. Oncotarget, 8: 47691–47708, 2017.
122.
RodriguezPC, OchoaAC, and Al-KhamiAA. Arginine metabolism in myeloid cells shapes innate and adaptive immunity. Front Immunol, 8: 93, 2017.
123.
Rodriguez-PradosJC, TravesPG, CuencaJ, RicoD, AragonesJ, Martin-SanzP, CascanteM, and BoscaL. Substrate fate in activated macrophages: a comparison between innate, classic, and alternative activation. J Immunol, 185: 605–614, 2010.
124.
RofstadEK, MathiesenB, HenriksenK, KindemK, and GalappathiK. The tumor bed effect: increased metastatic dissemination from hypoxia-induced up-regulation of metastasis-promoting gene products. Cancer Res, 65: 2387–2396, 2005.
125.
RoloffGW and GriffithsEA. When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter. Blood Adv, 2: 3070–3080, 2018.
126.
SanchoP, BarnedaD, and HeeschenC. Hallmarks of cancer stem cell metabolism. Br J Cancer, 114: 1305–1312, 2016.
127.
SanchoP, Burgos-RamosE, TaveraA, Bou KheirT, JagustP, SchoenhalsM, BarnedaD, SellersK, Campos-OlivasR, GranaO, VieraCR, YunevaM, SainzBJr., and HeeschenC. MYC/PGC-1alpha balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells. Cell Metab, 22: 590–605, 2015.
128.
SchockelL, GlasauerA, BasitF, BitscharK, TruongH, ErdmannG, AlgireC, HagebarthA, WillemsPH, KopitzC, KoopmanWJ, and HeroultM. Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth. Cancer Metab, 3: 11, 2015.
129.
ShackelfordDB, AbtE, GerkenL, VasquezDS, SekiA, LeblancM, WeiL, FishbeinMC, CzerninJ, MischelPS, and ShawRJ. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell, 23: 143–158, 2013.
130.
ShenJP, ZhaoD, SasikR, LuebeckJ, BirminghamA, Bojorquez-GomezA, LiconK, KlepperK, PekinD, BeckettAN, SanchezKS, ThomasA, KuoCC, DuD, RoguevA, LewisNE, ChangAN, KreisbergJF, KroganN, QiL, IdekerT, and MaliP. Combinatorial CRISPR-Cas9 screens for de novo mapping of genetic interactions. Nat Methods, 14: 573–576, 2017.
131.
ShiY, LimSK, LiangQ, IyerSV, WangHY, WangZ, XieX, SunD, ChenYJ, TabarV, GutinP, WilliamsN, De BrabanderJK, and ParadaLF. Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma. Nature, 567: 341–346, 2019.
132.
SmolkovaK, Plecita-HlavataL, BellanceN, BenardG, RossignolR, and JezekP. Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells. Int J Biochem Cell Biol, 43: 950–968, 2011.
133.
SrivastavaMK, SinhaP, ClementsVK, RodriguezP, and Ostrand-RosenbergS. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res, 70: 68–77, 2010.
134.
SrivastavaS, BarrettJN, and MoraesCT. PGC-1alpha/beta upregulation is associated with improved oxidative phosphorylation in cells harboring nonsense mtDNA mutations. Hum Mol Genet, 16: 993–1005, 2007.
135.
SteggerdaSM, BennettMK, ChenJ, EmberleyE, HuangT, JanesJR, LiW, MacKinnonAL, MakkoukA, MarguierG, MurrayPJ, NeouS, PanA, ParlatiF, RodriguezMLM, Van de VeldeLA, WangT, WorksM, ZhangJ, ZhangW, and GrossMI. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. J Immunother Cancer, 5: 101, 2017.
TelangS, O'NealJ, Imbert-FernandezY, ClemB, LypovaN, TapolskyGH, TrentJ, and ChesneyJ. Abstract 4478: 6-phosphofructo-2-kinase (PFKFB3): at the crossroads of resistance to targeted cancer therapies. Cancer Res, 75: 4478, 2015.
143.
TennantDA, DuranRV, and GottliebE. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer, 10: 267–277, 2010.
144.
TimmermanLA, HoltonT, YunevaM, LouieRJ, PadroM, DaemenA, HuM, ChanDA, EthierSP, van ‘t VeerLJ, PolyakK, McCormickF, and GrayJW. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell, 24: 450–465, 2013.
145.
TolcherA, FlahertyK, ShapiroGI, BerlinJ, WitzigT, HabermannT, BullockA, RockE, ElekesA, LinC, KosticD, OhiN, RascoD, PapadopoulosKP, PatnaikA, SmithL, and CoteGM. A first-in-human phase I study of OPB-111077, a small-molecule STAT3 and oxidative phosphorylation inhibitor, in patients with advanced cancers. Oncologist, 23: 658-e72, 2018.
146.
TurcanS, RohleD, GoenkaA, WalshLA, FangF, YilmazE, CamposC, FabiusAW, LuC, WardPS, ThompsonCB, KaufmanA, GuryanovaO, LevineR, HeguyA, VialeA, MorrisLG, HuseJT, MellinghoffIK, and ChanTA. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature, 483: 479–483, 2012.
147.
Vander HeidenMG.Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov, 10: 671–684, 2011.
148.
Vander HeidenMG, ChristofkHR, SchumanE, SubtelnyAO, SharfiH, HarlowEE, XianJ, and CantleyLC. Identification of small molecule inhibitors of pyruvate kinase M2. Biochem Pharmacol, 79: 1118–1124, 2010.
149.
VangapanduHV, AlstonB, MorseJ, AyresML, WierdaWG, KeatingMJ, MarszalekJR, and GandhiV. Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells. Oncotarget, 9: 24980–24991, 2018.
150.
VazquezF, LimJH, ChimH, BhallaK, GirnunG, PierceK, ClishCB, GranterSR, WidlundHR, SpiegelmanBM, and PuigserverP. PGC1alpha expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell, 23: 287–301, 2013.
151.
Vazquez-MartinA, ColomerR, BrunetJ, and MenendezJA. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting “HER2 super-expression” occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells. Int J Oncol, 31: 769–776, 2007.
WangQ, HardieRA, HoyAJ, van GeldermalsenM, GaoD, FazliL, SadowskiMC, BalabanS, SchreuderM, NagarajahR, WongJJ, MetierreC, PinelloN, OtteNJ, LehmanML, GleaveM, NelsonCC, BaileyCG, RitchieW, RaskoJE, and HolstJ. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. J Pathol, 236: 278–289, 2015.
155.
WangR, DillonCP, ShiLZ, MilastaS, CarterR, FinkelsteinD, McCormickLL, FitzgeraldP, ChiH, MungerJ, and GreenDR. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity, 35: 871–882, 2011.
156.
WarburgO.On the origin of cancer cells. Science, 123: 309–314, 1956.
157.
WardPS and ThompsonCB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell, 21: 297–308, 2012.
158.
WegielB, VuerichM, DaneshmandiS, and SethP. Metabolic switch in the tumor microenvironment determines immune responses to anti-cancer therapy. Front Oncol, 8: 284, 2018.
159.
Whitaker-MenezesD, Martinez-OutschoornUE, FlomenbergN, BirbeRC, WitkiewiczAK, HowellA, PavlidesS, TsirigosA, ErtelA, PestellRG, BrodaP, MinettiC, LisantiMP, and SotgiaF. Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue. Cell Cycle, 10: 4047–4064, 2011.
160.
WillinghamSB, HoPY, HotsonA, HillC, PiccioneEC, HsiehJ, LiuL, BuggyJJ, McCafferyI, and MillerRA. A2AR antagonism with CPI-444 induces antitumor responses and augments efficacy to anti-PD-(L)1 and anti-CTLA-4 in preclinical models. Cancer Immunol Res, 6: 1136–1149, 2018.
161.
WilsonPM, DanenbergPV, JohnstonPG, LenzHJ, and LadnerRD. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nat Rev Clin Oncol, 11: 282–298, 2014.
162.
WiseDR, DeBerardinisRJ, MancusoA, SayedN, ZhangXY, PfeifferHK, NissimI, DaikhinE, YudkoffM, McMahonSB, and ThompsonCB. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A, 105: 18782–18787, 2008.
163.
WongAL, SooRA, TanDS, LeeSC, LimJS, MarbanPC, KongLR, LeeYJ, WangLZ, ThuyaWL, SoongR, YeeMQ, ChinTM, CorderoMT, AsuncionBR, PangB, PervaizS, HirparaJL, SinhaA, XuWW, YuasaM, TsunodaT, MotoyamaM, YamauchiT, and GohBC. Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann Oncol, 26: 998–1005, 2015.
YangSX, PolleyE, and LipkowitzS. New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer. Cancer Treat Rev, 45: 87–96, 2016.
169.
YapTA, AhnertJR, Piha-PaulSA, FuS, JankuF, KarpDD, NaingA, DumbravaEEI, PantS, SubbiahV, TsimberidouAM, HongDS, RoseKM, XuQ, VellanoCP, MahendraM, JonesP, FrancescoMED, MarszalekJR, and Meric-BernstamF. Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors. J Clin Oncol, 37: 3014, 2019.
170.
YeJ, MancusoA, TongX, WardPS, FanJ, RabinowitzJD, and ThompsonCB. Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc Natl Acad Sci U S A, 109: 6904–6909, 2012.
YunJ, RagoC, CheongI, PagliariniR, AngenendtP, RajagopalanH, SchmidtK, WillsonJK, MarkowitzS, ZhouS, DiazLAJr., VelculescuVE, LengauerC, KinzlerKW, VogelsteinB, and PapadopoulosN.Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science, 325: 1555–1559, 2009.
173.
YunevaMO, FanTW, AllenTD, HigashiRM, FerrarisDV, TsukamotoT, MatesJM, AlonsoFJ, WangC, SeoY, ChenX, and BishopJM. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab, 15: 157–170, 2012.
174.
ZaidiN, SwinnenJV, and SmansK. ATP-citrate lyase: a key player in cancer metabolism. Cancer Res, 72: 3709–3714, 2012.
175.
ZhaiL, SprangerS, BinderDC, GritsinaG, LauingKL, GilesFJ, and WainwrightDA. Molecular pathways: targeting IDO1 and other tryptophan dioxygenases for cancer immunotherapy. Clin Cancer Res, 21: 5427–5433, 2015.
176.
ZhaoD, BadurMG, LuebeckJ, MaganaJH, BirminghamA, SasikR, AhnCS, IdekerT, MetalloCM, and MaliP. Combinatorial CRISPR-Cas9 metabolic screens reveal critical redox control points dependent on the KEAP1-NRF2 regulatory axis. Mol Cell, 69: 699.e7–708.e7, 2018.
177.
ZhouW, HanWF, LandreeLE, ThupariJN, PinnML, BililignT, KimEK, VadlamudiA, MedghalchiSM, El MeskiniR, RonnettGV, TownsendCA, and KuhajdaFP. Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells. Cancer Res, 67: 2964–2971, 2007.
178.
ZongH, ZhangY, YouY, CaiT, and WangY. Decreased Warburg effect induced by ATP citrate lyase suppression inhibits tumor growth in pancreatic cancer. Med Oncol, 32: 85, 2015.
